deltatrials
Recruiting PHASE4 INTERVENTIONAL 1-arm NCT07042581

A Study of Revaree Plus in People With Breast Cancer

Evaluation of Revaree Plus in Women With Breast Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Breast Cancer Hormone Receptor Positive Breast Carcinoma Hormone Receptor Positive Malignant Neoplasm of Breast Hormone-receptor-positive Breast Cancer Stage 0 Breast Cancer Stage 0 Breast Carcinoma Stage I Breast Cancer Stage II Breast Cancer Stage II Breast Carcinoma Stage III Breast Cancer Stage III Breast Carcinoma
Interventions Revaree Plus
Updated 3 times since 2025 Last updated: Feb 4, 2026 Started: Jun 20, 2025 Primary completion: Jun 20, 2029 Completion: Jun 20, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Breast Cancer and Hormone Receptor Positive Breast Carcinoma and is currently actively recruiting participants. Memorial Sloan Kettering Cancer Center leads this study, which shows 3 recorded versions since 2025 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Jul 2025 – ~Dec 2025 · 5 months · monthly snapshotRecruiting~Dec 2025 – ~Feb 2026 · 2 months · monthly snapshotRecruiting~Feb 2026 – present · 7 months · monthly snapshotRecruiting

Change History

3 versions recorded

  1. Feb 2026 — Present [monthly]

    Recruiting PHASE4

  2. Dec 2025 — Feb 2026 [monthly]

    Recruiting PHASE4

  3. Jul 2025 — Dec 2025 [monthly]

    Recruiting PHASE4

    First recorded

Jun 2025

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations